期刊文献+

三种方案治疗难治复发性白血病临床对比研究 被引量:2

下载PDF
导出
摘要 目的比较并观察三种化疗方案治疗难治、复发急性白血病(AL)的疗效及不良反应。方法将104例难治、复发AL患者分为三组,采用三种不同的化疗方案治疗,其中32例接受大剂量阿糖胞苷(HD-Ara-c)治疗,28例接受去甲氧柔红霉素加阿糖胞苷(IDA)治疗,44例接受氟达拉滨加阿糖胞苷加粒细胞集落刺激因子(FLAG)治疗。结果三种化疗方案治疗难治、复发AL总有效率分别为46.9%、36.3%和77.3%,差异有统计学意义(P<0.05),FLAG方案缓解率高于其他两组。不良反应方面,FLAG方案骨髓抑制时间更长,中性粒细胞缺乏率三组间差异无统计学意义,非血液学不良反应三组差异无统计学意义。结论 FLAG方案是难治、复发AL治疗的一个更好选择,但其骨髓抑制严重,继发感染机会增加。
作者 宋国庆 杨瑞
出处 《宁夏医科大学学报》 2012年第11期1171-1173,共3页 Journal of Ningxia Medical University
  • 相关文献

参考文献8

  • 1张之南.血液病诊断及疗效标准[M].3版.北京:科学出版社,2008:1. 被引量:83
  • 2Belhabri A,Thdmas X,Wattel E, et al. ALL trans retin- oic acid in combination with intermediate -dose cytara- bine and idarubicin in patients with relapsed or refractory non promydocytic acute myeloid Leukemia: a phase Ⅱ randomized trial [ J ] Hematol J, 2002,3:49 - 55. 被引量:1
  • 3Jackson GH. Use of fludarabine in the treatment of acute myeloid Leukemia[ J]. Hematol J,2004,5:62 - 67. 被引量:1
  • 4Gandhi V, Estey E, Keating M J, et al. Fludarabine po- tentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy [ J ]. J Clin Oncol, 1993,11:116 - 124. 被引量:1
  • 5Yamada K, Furusaw AS, Saito K, et al. Concurrent use of granulocyte colony - stimulating factor with low - dose cytosine arabinaside and aclarubcin for previously treated acute myelogenous leukemia: a pilot study [ J ]. Le- ttemia, 1995,9 : 10 - 14. 被引量:1
  • 6杨斌,曹祥山,王彪,董伟民,华晓莹,凌云,顾伟英,钱新瑜,钱思轩,李建勇.FLAG方案与IA方案治疗初治急性髓系白血病临床对比观察[J].中华血液学杂志,2012,33(2):141-143. 被引量:6
  • 7Dighiero G. Adverse and beneficial immunological effects of purine nucleoside analogues [ J ]. Hematoc Cell Ther, 1996,38 ( supol 2) :575 -581. 被引量:1
  • 8焦洋,许莹,李太生,武永吉.B细胞性非霍奇金淋巴瘤患者应用氟达拉滨化疗方案治疗后外周血淋巴细胞表型特点分析[J].临床血液学杂志,2007,20(5):259-261. 被引量:7

二级参考文献17

  • 1支雅军,万斌,戴辉,宋燕萍.利妥昔单抗联合CHOP方案治疗非霍奇金淋巴瘤的临床观察[J].临床血液学杂志,2005,18(3):178-179. 被引量:3
  • 2华东FLAG方案治疗协作组,李军民,沈志祥.氟达拉滨联合阿糖胞苷和粒细胞集落刺激因子治疗复发和难治性急性髓系白血病[J].中华血液学杂志,2005,26(11):684-685. 被引量:17
  • 3Higashi Y,Turzanski J,Pallis M,et al.Contrasting in vitro effects for the combination of fludarabine,cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukemia.Br J Haematol,2000,111:565-569. 被引量:1
  • 4Jackson G,Taylor P,Smith GM,et al.A multicentre,open,noncomparative phase Ⅱ study of a combination of fludarabine phosphate,cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol,2001,112:127-137. 被引量:1
  • 5Kantarjian H,Wang X,Plunkett WK,et al.Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine,cytarabine,and granulocyte colony-stimulating factor results in improved event-free survival.Cancer,2008,113:3181-3185. 被引量:1
  • 6Litvinova E,Peters GJ,Broekhuizen R,et al.The effect of GCSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia.Intern J Oncol,2004,25:1823-1829. 被引量:1
  • 7ZINZANI P L. Clinical experience with fludarabine in indolent non-Hodgkin's lymphoma [J]. Hematol J, 2004, 5 Suppl 1:S38-S49. 被引量:1
  • 8DIGHIERO G. Adverse and benelicial immunological effects of purine nucleoside analogues [J]. Hematol Cell Ther, 1996, 38 Suppl 2:S75-S81. 被引量:1
  • 9GOODMAN E R, FIEDOR P S, FEIN S, et al. Fludarabine phosphate: A DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity[J]. Am Surg, 1996, 62:435-442. 被引量:1
  • 10MORRISON V A, RAI K R, PETERSON B L, et al. Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011[J]. J Clin Oncol, 2001, 19:3611-3621. 被引量:1

共引文献93

同被引文献12

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部